Zota Health Care Limited’s Q2 FY27 results paired 54.58% growth in revenue from operations with a wider consolidated net loss of ₹259.6 million for the quarter ended Sept. 30, 2026.
The National Stock Exchange of India filing put revenue from operations at ₹19,933.14 lakh, or about ₹1.99 billion, against ₹12,894.82 lakh a year earlier. The consolidated net loss totaled ₹2,596.02 lakh, compared with ₹1,619.38 lakh in Q2 FY26.
Zota’s Q2 FY27 press release filed with the NSE said Davaindia sales reached ₹1.68 billion, up 76.25% from ₹955.86 million a year earlier. The pharmacy chain had 2,840 stores on Sept. 30, 2026, including 1,859 COCO and 981 FOFO locations. Quarterly footfall rose to 6.62 million from 4.35 million.
Zota said it slowed Davaindia store additions after several quarters of significant expansion. It added 20 stores and closed five FOFO locations in Q2 FY27. The company plans to pick up the pace of additions in H2 FY27, with higher productivity at existing stores, efficient operations and cash generation among its priorities.
Zota Health Care Chairman Ketan Kumar Zota said the company’s focus remained on “sustainable and disciplined growth.” Its release put consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) at ₹791.72 lakh, or ₹7.9172 crore, with a 3.97% margin, compared with ₹795.71 lakh and 6.17% a year earlier. NDTV Profit’s account of Nirmal Bang’s research cited Q2 EBITDA of ₹3.1 crore, while Zota’s release reported ₹7.9172 crore.
Separately, NDTV Profit reported that Nirmal Bang Institutional Research kept its Buy rating on Zota shares and lowered its target price to ₹1,670 from ₹1,679. NDTV Profit said the brokerage projected 62% compound annual revenue growth from FY26 to FY28E, citing new store openings, operational gains and a broader network. The outlet also reported that the brokerage used a 20-times September FY30E enterprise value-to-EBITDA valuation.
